Download PDF
Clin Colon Rectal Surg 2023; 36(02): 105-111
DOI: 10.1055/s-0042-1760679
Review Article

Role of Bacteria in the Development of Colorectal Cancer

Ryan M. Thomas
1   Department of Surgery, University of Florida, Gainesville, Florida
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States. Once limited to older populations, the incidence of CRC in patients under the age of 50 years is increasing and the etiology for this is uncertain. One hypothesis lies on the impact of the intestinal microbiome. The intestinal microbiome, composed primarily of bacteria but also viruses, fungi, and archaea, has been shown to regulate CRC development and progression both in vitro and in vivo. In this review, the role and intersection of the bacterial microbiome in various stages of clinical CRC development and management are discussed beginning with CRC screening. Various mechanisms whereby the microbiome has been shown to modulate CRC development including the influence of diet on the microbiome, bacterial-induced injury to the colonic epithelium, bacterial-produced toxins, and alteration of normal cancer immunosurveillance by the microbiome are discussed. Finally, the influence of microbiome on the response of CRC to treatment is discussed while highlighting ongoing clinical trials. The complexities of the microbiome and its role in CRC development and progression have become apparent and will require ongoing commitment to translate laboratory findings into meaningful clinical results that will aid more than 150,000 patients that develop CRC every year.

Keywords

microbiome - oncobiome - colorectal cancer - colon cancer - chemotherapy - immunotherapy


Publication History

Article published online:
25 January 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020; 8 (02) e180-e190
    CrossrefPubMedGoogle Scholar
  • 2 Akimoto N, Ugai T, Zhong R. et al. Rising incidence of early-onset colorectal cancer – a call to action. Nat Rev Clin Oncol 2021; 18 (04) 230-243
    CrossrefPubMedGoogle Scholar
  • 3 Davidson KW, Barry MJ, Mangione CM. et al; US Preventive Services Task Force. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA 2021; 325 (19) 1965-1977
    CrossrefPubMedGoogle Scholar
  • 4 Imperiale TF, Ransohoff DF, Itzkowitz SH. et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 370 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 5 Vogelstein B, Fearon ER, Hamilton SR. et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319 (09) 525-532
    CrossrefPubMedGoogle Scholar
  • 6 Nakatsu G, Li X, Zhou H. et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun 2015; 6: 8727
    CrossrefPubMedGoogle Scholar
  • 7 Zeller G, Tap J, Voigt AY. et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol 2014; 10 (11) 766
    CrossrefPubMedGoogle Scholar
  • 8 Peters BA, Dominianni C, Shapiro JA. et al. The gut microbiota in conventional and serrated precursors of colorectal cancer. Microbiome 2016; 4 (01) 69
    CrossrefPubMedGoogle Scholar
  • 9 Rezasoltani S, Asadzadeh Aghdaei H, Dabiri H, Akhavan Sepahi A, Modarressi MH, Nazemalhosseini Mojarad E. The association between fecal microbiota and different types of colorectal polyp as precursors of colorectal cancer. Microb Pathog 2018; 124: 244-249
    CrossrefPubMedGoogle Scholar
  • 10 Kostic AD, Chun E, Robertson L. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14 (02) 207-215
    CrossrefPubMedGoogle Scholar
  • 11 Kartal E, Schmidt TSB, Molina-Montes E. et al; MAGIC Study investigators, PanGenEU Study investigators. A faecal microbiota signature with high specificity for pancreatic cancer. Gut 2022; 71 (07) 1359-1372
    CrossrefPubMedGoogle Scholar
  • 12 O'Keefe SJD, Li JV, Lahti L. et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun 2015; 6: 6342
    CrossrefPubMedGoogle Scholar
  • 13 Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology 2015; 148 (06) 1244-60.e16
    CrossrefPubMedGoogle Scholar
  • 14 Arayici ME, Mert-Ozupek N, Yalcin F, Basbinar Y, Ellidokuz H. Soluble and insoluble dietary fiber consumption and colorectal cancer risk: a systematic review and meta-analysis. Nutr Cancer 2022; 74 (07) 2412-2425
    CrossrefPubMedGoogle Scholar
  • 15 Feng Q, Liang S, Jia H. et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun 2015; 6: 6528
    CrossrefPubMedGoogle Scholar
  • 16 Attene-Ramos MS, Wagner ED, Gaskins HR, Plewa MJ. Hydrogen sulfide induces direct radical-associated DNA damage. Mol Cancer Res 2007; 5 (05) 455-459
    CrossrefPubMedGoogle Scholar
  • 17 Ijssennagger N, van der Meer R, van Mil SWC. Sulfide as a mucus barrier-breaker in inflammatory bowel disease?. Trends Mol Med 2016; 22 (03) 190-199
    CrossrefPubMedGoogle Scholar
  • 18 Nguyen LH, Cao Y, Hur J. et al. The sulfur microbial diet is associated with increased risk of early-onset colorectal cancer precursors. Gastroenterology 2021; 161 (05) 1423-1432.e4
    CrossrefPubMedGoogle Scholar
  • 19 Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 2012; 7 (06) e39743
    CrossrefPubMedGoogle Scholar
  • 20 Yazici C, Wolf PG, Kim H. et al. Race-dependent association of sulfidogenic bacteria with colorectal cancer. Gut 2017; 66 (11) 1983-1994
    CrossrefPubMedGoogle Scholar
  • 21 Nguyen LH, Ma W, Wang DD. et al. Association between sulfur-metabolizing bacterial communities in stool and risk of distal colorectal cancer in men. Gastroenterology 2020; 158 (05) 1313-1325
    CrossrefPubMedGoogle Scholar
  • 22 Bingham SA, Day NE, Luben R. et al; European Prospective Investigation into Cancer and Nutrition. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003; 361 (9368): 1496-1501
    CrossrefPubMedGoogle Scholar
  • 23 Peters U, Sinha R, Chatterjee N. et al; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet 2003; 361 (9368): 1491-1495
    CrossrefPubMedGoogle Scholar
  • 24 Song M, Chan AT. Environmental factors, gut microbiota, and colorectal cancer prevention. Clin Gastroenterol Hepatol 2019; 17 (02) 275-289
    CrossrefPubMedGoogle Scholar
  • 25 Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 1982; 83 (02) 424-429
    CrossrefPubMedGoogle Scholar
  • 26 Macfarlane GT, Englyst HN. Starch utilization by the human large intestinal microflora. J Appl Bacteriol 1986; 60 (03) 195-201
    CrossrefPubMedGoogle Scholar
  • 27 Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MAR. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunology 2016; 5 (04) e73
    CrossrefPubMedGoogle Scholar
  • 28 Bordonaro M, Lazarova DL, Sartorelli AC. Butyrate and Wnt signaling: a possible solution to the puzzle of dietary fiber and colon cancer risk?. Cell Cycle 2008; 7 (09) 1178-1183
    CrossrefPubMedGoogle Scholar
  • 29 Bultman SJ. Molecular pathways: gene-environment interactions regulating dietary fiber induction of proliferation and apoptosis via butyrate for cancer prevention. Clin Cancer Res 2014; 20 (04) 799-803
    CrossrefPubMedGoogle Scholar
  • 30 Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem 2008; 19 (09) 587-593
    CrossrefPubMedGoogle Scholar
  • 31 Chen H-M, Yu YN, Wang JL. et al. Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am J Clin Nutr 2013; 97 (05) 1044-1052
    CrossrefPubMedGoogle Scholar
  • 32 Chen D, Jin D, Huang S. et al. Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota. Cancer Lett 2020; 469: 456-467
    CrossrefPubMedGoogle Scholar
  • 33 Johansson MEV, Larsson JMH, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A 2011; 108 (Suppl. 01) 4659-4665
    CrossrefPubMedGoogle Scholar
  • 34 Johansson MEV, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 2008; 105 (39) 15064-15069
    CrossrefPubMedGoogle Scholar
  • 35 Ott SJ, Musfeldt M, Wenderoth DF. et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53 (05) 685-693
    CrossrefPubMedGoogle Scholar
  • 36 Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126 (06) 1620-1633
    CrossrefPubMedGoogle Scholar
  • 37 Lleal M, Sarrabayrouse G, Willamil J, Santiago A, Pozuelo M, Manichanh C. A single faecal microbiota transplantation modulates the microbiome and improves clinical manifestations in a rat model of colitis. EBioMedicine 2019; 48: 630-641
    CrossrefPubMedGoogle Scholar
  • 38 Willemsen LEM, Koetsier MA, van Deventer SJH, van Tol EAF. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 2003; 52 (10) 1442-1447
    CrossrefPubMedGoogle Scholar
  • 39 Roberts CL, Keita AV, Duncan SH. et al. Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010; 59 (10) 1331-1339
    CrossrefPubMedGoogle Scholar
  • 40 Chassaing B, Koren O, Goodrich JK. et al. Corrigendum: dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2016; 536 (7615): 238
    CrossrefPubMedGoogle Scholar
  • 41 Liu L, Dong W, Wang S. et al. Deoxycholic acid disrupts the intestinal mucosal barrier and promotes intestinal tumorigenesis. Food Funct 2018; 9 (11) 5588-5597
    CrossrefPubMedGoogle Scholar
  • 42 Ocvirk S, O'Keefe SJ. Influence of bile acids on colorectal cancer risk: potential mechanisms mediated by diet – gut microbiota interactions. Curr Nutr Rep 2017; 6 (04) 315-322
    CrossrefPubMedGoogle Scholar
  • 43 Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-271
    CrossrefPubMedGoogle Scholar
  • 44 Takiishi T, Fenero CIM, Câmara NOS. Intestinal barrier and gut microbiota: shaping our immune responses throughout life. Tissue Barriers 2017; 5 (04) e1373208
    CrossrefPubMedGoogle Scholar
  • 45 Elphick DA, Mahida YR. Paneth cells: their role in innate immunity and inflammatory disease. Gut 2005; 54 (12) 1802-1809
    CrossrefPubMedGoogle Scholar
  • 46 Aghamajidi A, Maleki Vareki S. The effect of the gut microbiota on systemic and anti-tumor immunity and response to systemic therapy against cancer. Cancers (Basel) 2022; 14 (15) 3563
    CrossrefPubMedGoogle Scholar
  • 47 Yu AI, Zhao L, Eaton KA. et al. Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis. Cell Rep 2020; 31 (01) 107471
    CrossrefPubMedGoogle Scholar
  • 48 Ivanov II, Atarashi K, Manel N. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139 (03) 485-498
    CrossrefPubMedGoogle Scholar
  • 49 Overacre-Delgoffe AE, Bumgarner HJ, Cillo AR. et al. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity 2021; 54 (12) 2812-2824.e4
    CrossrefPubMedGoogle Scholar
  • 50 Wilson MR, Jiang Y, Villalta PW. et al. The human gut bacterial genotoxin colibactin alkylates DNA. Science 2019; 363 (6428): eaar7785
    CrossrefPubMedGoogle Scholar
  • 51 Arthur JC, Perez-Chanona E, Mühlbauer M. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012; 338 (6103): 120-123
    CrossrefPubMedGoogle Scholar
  • 52 Tomkovich S, Yang Y, Winglee K. et al. Locoregional effects of microbiota in a preclinical model of colon carcinogenesis. Cancer Res 2017; 77 (10) 2620-2632
    CrossrefPubMedGoogle Scholar
  • 53 Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A. et al; Genomics England Research Consortium. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli . Nature 2020; 580 (7802): 269-273
    CrossrefPubMedGoogle Scholar
  • 54 Hwang S, Lee CG, Jo M. et al. Enterotoxigenic Bacteroides fragilis infection exacerbates tumorigenesis in AOM/DSS mouse model. Int J Med Sci 2020; 17 (02) 145-152
    CrossrefPubMedGoogle Scholar
  • 55 Boleij A, Hechenbleikner EM, Goodwin AC. et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis 2015; 60 (02) 208-215
    CrossrefPubMedGoogle Scholar
  • 56 Clay SL, Fonseca-Pereira D, Garrett WS. Colorectal cancer: the facts in the case of the microbiota. J Clin Invest 2022; 132 (04) e155101
    CrossrefPubMedGoogle Scholar
  • 57 Gur C, Ibrahim Y, Isaacson B. et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 2015; 42 (02) 344-355
    CrossrefPubMedGoogle Scholar
  • 58 Mitsuhashi K, Nosho K, Sukawa Y. et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 2015; 6 (09) 7209-7220
    CrossrefPubMedGoogle Scholar
  • 59 Hieken TJ, Chen J, Hoskin TL. et al. The microbiome of aseptically collected human breast tissue in benign and malignant disease. Sci Rep 2016; 6: 30751
    CrossrefPubMedGoogle Scholar
  • 60 Rubinstein MR, Baik JE, Lagana SM. et al. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. EMBO Rep 2019; 20 (04) e47638
    CrossrefPubMedGoogle Scholar
  • 61 Abed J, Emgård JE, Zamir G. et al. Fap2 Mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe 2016; 20 (02) 215-225
    CrossrefPubMedGoogle Scholar
  • 62 Meng Q, Gao Q, Mehrazarin S. et al. Fusobacterium nucleatum secretes amyloid-like FadA to enhance pathogenicity. EMBO Rep 2021; 22 (07) e52891
    CrossrefPubMedGoogle Scholar
  • 63 Yu T, Guo F, Yu Y. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017; 170 (03) 548-563.e16
    CrossrefPubMedGoogle Scholar
  • 64 Vétizou M, Pitt JM, Daillère R. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350 (6264): 1079-1084
    CrossrefPubMedGoogle Scholar
  • 65 Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271 (5256): 1734-1736
    CrossrefPubMedGoogle Scholar
  • 66 He D, Li X, An R. et al. Response to PD-1-based immunotherapy for non-small cell lung cancer altered by gut microbiota. Oncol Ther 2021; 9 (02) 647-657
    CrossrefPubMedGoogle Scholar
  • 67 Le DT, Durham JN, Smith KN. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357 (6349): 409-413
    CrossrefPubMedGoogle Scholar
  • 68 Mager LF, Burkhard R, Pett N. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 2020; 369 (6510): 1481-1489
    CrossrefPubMedGoogle Scholar
  • 69 Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol 2017; 14 (06) 356-365
    CrossrefPubMedGoogle Scholar
  • 70 Takasuna K, Hagiwara T, Hirohashi M. et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56 (16) 3752-3757
    PubMedGoogle Scholar
  • 71 Bhatt AP, Pellock SJ, Biernat KA. et al. Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy. Proc Natl Acad Sci U S A 2020; 117 (13) 7374-7381
    CrossrefPubMedGoogle Scholar
  • 72 Jobin C. Precision medicine using microbiota. Science 2018; 359 (6371): 32-34
    CrossrefPubMedGoogle Scholar
  • 73 Thomas RM, Jobin C. The microbiome and cancer: is the “oncobiome” mirage real?. Trends Cancer 2015; 1 (01) 24-35
    CrossrefPubMedGoogle Scholar